Showing results (271-280 of 453) with videos related to
Sort By:
Pageof 46
Cancer Discovery|April 12, 2022
Precision Combination Therapies Based on Recurrent Oncogenic CoalterationsXubin Li, Elisabeth K Dowling, Gonghong Yan, et al.Molecular Oncology|June 16, 2017
Analysis of mutant allele fractions in driver genes in colorectal cancer - biological and clinical insightsRodrigo Dienstmann, Elena Elez, Guillem Argiles, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 27, 2014
First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and gliomaJordi Rodon, Michael A Carducci, Juan M Sepulveda-Sánchez, et al.Journal for Immunotherapy of Cancer|August 21, 2023
T-cell receptor beta variable gene polymorphism predicts immune-related adverse events during checkpoint blockade immunotherapyBettzy Stephen, Joud Hajjar, Shrutii Sarda, et al.Journal for Immunotherapy of Cancer|March 20, 2020
Phase 2 study of pembrolizumab in patients with advanced rare cancersAung Naing, Funda Meric-Bernstam, Bettzy Stephen, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2021
ATR Inhibition Induces CDK1-SPOP Signaling and Enhances Anti-PD-L1 Cytotoxicity in Prostate CancerZhe Tang, Patrick G Pilié, Chuandong Geng, et al.The Lancet. Respiratory Medicine|April 9, 2021
Efficacy and safety of pembrolizumab in patients with advanced mesothelioma in the open-label, single-arm, phase 2 KEYNOTE-158 studyTimothy A Yap, Kazuhiko Nakagawa, Nobukazu Fujimoto, et al.European Journal of Cancer (Oxford, England : 1990)|April 17, 2018
First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13)Andreas Wicki, Nicholas Brown, Alexandros Xyrafas, et al.Neuro-Oncology|February 24, 2016
A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastomaAlba A Brandes, Antoine F Carpentier, Santosh Kesari, et al.Journal for Immunotherapy of Cancer|February 16, 2021
Integrating genome-wide CRISPR immune screen with multi-omic clinical data reveals distinct classes of tumor intrinsic immune regulatorsJiakai Hou, Yunfei Wang, Leilei Shi, et al.Pageof 46